Top-Rated StocksTop-RatedNASDAQ:TSHA Taysha Gene Therapies (TSHA) Stock Price, News & Analysis $5.02 -0.14 (-2.71%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$5.02 0.00 (0.00%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Taysha Gene Therapies Stock (NASDAQ:TSHA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Taysha Gene Therapies alerts:Sign Up Key Stats Today's Range$4.96▼$5.2850-Day Range$5.01▼$6.6852-Week Range$2.71▼$7.30Volume9.12 million shsAverage Volume2.55 million shsMarket Capitalization$1.64 billionP/E RatioN/ADividend YieldN/APrice Target$12.77Consensus RatingBuy Company Overview Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company developing gene therapies for severe monogenic diseases of the central nervous system. The company focuses on disorders in which a missing or defective gene contributes to neurological disease and uses adeno-associated virus (AAV) vectors to deliver functional genetic material to targeted cells. Taysha’s development programs have included TSHA-102, an investigational gene therapy for Rett syndrome, and earlier programs such as TSHA-120 for giant axonal neuropathy and TSHA-101 for GM1 gangliosidosis. Its programs are designed to address rare diseases with limited or no approved treatment options, and the company’s candidates remain subject to clinical testing and regulatory review. Founded in 2019 and headquartered in Dallas, Texas, Taysha established its research and development efforts through collaborations involving the University of Texas Southwestern Medical Center. The company conducts development activities through clinical and research collaborations and is focused primarily on advancing therapies for patients with rare neurological conditions in the United States and other potential treatment markets.AI Generated. May Contain Errors. Read More Taysha Gene Therapies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreTSHA MarketRank™: Taysha Gene Therapies scored higher than 64% of companies evaluated by MarketBeat, and ranked 244th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingTaysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialTaysha Gene Therapies has a consensus price target of $12.77, representing about 154.4% upside from its current price of $5.02.Amount of Analyst CoverageTaysha Gene Therapies has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Taysha Gene Therapies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Taysha Gene Therapies are expected to grow in the coming year, from ($0.52) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Taysha Gene Therapies is -11.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Taysha Gene Therapies is -11.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTaysha Gene Therapies has a P/B Ratio of 5.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Taysha Gene Therapies' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.88% of the float of Taysha Gene Therapies has been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 19.4, which indicates bearish sentiment.Change versus previous monthShort interest in Taysha Gene Therapies has recently increased by 0.13%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTaysha Gene Therapies does not currently pay a dividend.Dividend GrowthTaysha Gene Therapies does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.94 News SentimentTaysha Gene Therapies has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Taysha Gene Therapies this week, compared to 4 articles on an average week.Search Interest4 people have searched for TSHA on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows7 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Taysha Gene Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,248,000.00 in company stock.Percentage Held by Insiders3.48% of the stock of Taysha Gene Therapies is held by insiders.Percentage Held by Institutions77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Taysha Gene Therapies' insider trading history. Receive TSHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TSHA Stock News HeadlinesWolfe Research Initiates Coverage on Taysha Gene Therapies (NASDAQ:TSHA)September 19 at 1:54 AM | americanbankingnews.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by AnalystsSeptember 17 at 3:46 AM | americanbankingnews.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.September 19 at 1:00 AM | Banyan Hill Publishing (Ad)Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest ApprovalSeptember 11, 2026 | seekingalpha.comThese 3 Risky Stocks Could Be Sitting on 100% Upside (TSHA)Analysts see high-risk, high-reward potential in Red Cat Holdings, Taysha Gene Therapies, and Solaris Resources, each projected to roughly double despite significant company-specific risks.September 7, 2026 | marketbeat.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 4, 2026 | globenewswire.comTaysha Gene Therapies Earnings Call Highlights Pivotal ProgressAugust 23, 2026 | tipranks.comTaysha Gene Therapies (TSHA) Q2 2026 Earnings CallAugust 18, 2026 | finance.yahoo.comSee More Headlines TSHA Stock Analysis - Frequently Asked Questions How have TSHA shares performed this year? Taysha Gene Therapies' stock was trading at $5.50 at the beginning of the year. Since then, TSHA stock has decreased by 8.7% and is now trading at $5.02. How were Taysha Gene Therapies' earnings last quarter? Taysha Gene Therapies, Inc. (NASDAQ:TSHA) posted its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.02. Read the conference call transcript. When did Taysha Gene Therapies IPO? Taysha Gene Therapies (TSHA) raised $150 million in an initial public offering on Thursday, September 24th 2020. The company issued 7,869,566 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager. Who are Taysha Gene Therapies' major shareholders? Taysha Gene Therapies' top institutional investors include Wellington Management Group LLP (1.22%), Seven Fleet Capital Management LP (0.46%), Bank of New York Mellon Corp (0.24%) and Squarepoint Ops LLC (0.17%). Insiders that own company stock include Sean P Nolan, Paul B Manning, Kamran Alam and Sukumar Nagendran. View institutional ownership trends. How do I buy shares of Taysha Gene Therapies? Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Taysha Gene Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Taysha Gene Therapies investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alphabet (GOOG), Visa (V) and Walt Disney (DIS). Company Calendar Last Earnings8/11/2026Today9/19/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 TSHA's financial health is in the Green zone, according to TradeSmith. TSHA has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TSHA CIK1806310 Webwww.tayshagtx.com Phone214-612-0000FaxN/AEmployees99Year Founded2020Price Target and Rating Average Price Target for Taysha Gene Therapies$12.77 High Price Target$17.00 Low Price Target$10.00 Potential Upside/Downside+154.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$109 million Net MarginsN/A Pretax Margin-2,728.04% Return on Equity-56.19% Return on Assets-41.84% Debt Debt-to-Equity Ratio0.13 Current Ratio17.76 Quick Ratio17.76 Sales & Book Value Annual Sales$9.77 million Price / Sales167.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / Book5.58Miscellaneous Outstanding Shares325,830,000Free Float314,495,000Market Cap$1.64 billion OptionableOptionable Beta1.19 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:TSHA) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TSHA Stock Alerts